Japan Pharma Review: Outlook to 2017: New research report available at Fast Market Research

Sept. 29, 2012 - PRLog -- Japan's pharmaceutical industry is in the midst of a defining period. The sector has evolved dramatically over the past decade, as companies attempt to gain ground on their Western peers in meeting the demands of global healthcare markets.

Scope
* Analysis of Japan Pharma's domestic and international competitive environment
* Assess Japan Pharma's strategy for driving growth and extending its global reach

Highlights

While the top 10 companies in Japan Pharma are dominant within their domestic market, generating more than half of overall prescription pharma revenues in Japan, a range of factors have provided the impetus for companies to expand their global footprint.

Reasons to Get this Report
* Evaluate the drivers and resistors of sales growth for the Japan Pharma peer set, both in its domestic market and overseas
* Assess Japan Pharma's strategic opportunities to bolster its performance

Report Table of Contents:

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/464840_japan_pharma_review_out...
------------------------------------------------------------

SCOPE OF ANALYSIS

* PharmaVitae Explorer database

EXECUTIVE SUMMARY

* Key findings
* Japan Pharma's expanding global footprint

* Closing the gap on Big Pharma
* Japan still a stronghold for domestic players
* US revenues set for 25% decline; focus shifting towards areas of unmet need
* Takeda - leading the trend in globalization
* External strategies employed to reinforce long-term growth

HISTORICAL EVOLUTION OF JAPAN PHARMA

* Introduction

* Corporate evolution of Japan Pharma

JAPAN PHARMA DOMESTIC MARKET ANALYSIS: FOCUS ON JAPAN

* Key domestic growth drivers

* Aging Japanese population
* Japan Pharma focus shifting towards chronic disease areas

* Key domestic growth resistors

* Domestic outlook is positive overall despite downward pressures

JAPAN PHARMA INTERNATIONAL MARKET ANALYSIS: FOCUS ON GLOBALIZATION

* International drivers and resistors

* Japan Pharma geographical positioning
* Overseas products offer greater likelihood of reaching blockbuster revenues
* Upsurge in overseas acquisitions by Japan Pharma

* Financial catalysts of Japan Pharma's international position

* Strong balance sheet provides springboard for M&A
* Currency fluctuations have greatly enhanced the overseas purchasing power of Japan Pharma

* Product portfolio dynamics

* Positive impact of externally sourced products on sales performance
* Pipelines are increasingly focused on international development
* Shift towards oncology drug development
* Expiry impact - generic erosion in the US is trigger for M&A
* Shift away from the blockbuster model

APPENDIX

* References
* Exchange rates

TABLES

* Table: Datamonitor's established pharmaceutical company coverage, 2012
* Table: Top 10 companies in Japan Pharma, sales ($m), 2005-17
* Table: Exchange rates, 2012

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: Evolution of Japan Pharma's corporate strategy
* Figure: Top 10 prescription pharmaceutical companies in Japan in 2011 (Japan FY2012)
* Figure: Global prescription pharmaceutical sales, split by region (% of total sales)
* Figure: Summary of drivers and resistors in the domestic Japanese market
* Figure: Leading pharmaceutical companies' prescription pharmaceutical sales in Japan, 2011
* Figure: Japanese population distributed by age (millions of people)
* Figure: Japan Pharma domestic growth forecast by therapy area
* Figure: Generic usage by volume in major markets
* Figure: Japan Pharma domestic sales by age of drug (in years)
* Figure: Japan Pharma combined sales forecast in domestic market
* Figure: Summary of drivers and resistors impacting Japan Pharma globalization strategy
* Figure: Global pharmaceutical sales by company, 2011
* Figure: Geographical focus of Japan Pharma vs Global Pharma, 2011
* Figure: Overseas sales of Japan Pharma, 2005-11
* Figure: Japan Pharma overseas market focus, 2011
* Figure: Japan Pharma's top 20 products by sales, 2011
* Figure: Japan Pharma's cash vs debt, 2006-11
* Figure: Historical exchange rate of yen vs US dollar, euro, and pound, January 2007 to January 2012
* Figure: Overseas sales of Japan Pharma by product source, 2005-17
* Figure: Japan Pharma global clinical development pipeline, Phase I to registration
* Figure: Japan Pharma global clinical development pipeline by therapy area
* Figure: Japan Pharma expiry sales forecast, 2011-17
* Figure: Overseas sales of top 10 Japan Pharma companies by drug value

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.